\
&
Contact us
\
&
Contact us
The starting point of this initiative is to reduce the current fragmentation of innovation ecosystems all over Europe. Consequently this initiative provides for renewed and reinforced coordination and cooperation mechanisms with Member states and associated countries but private initiatives can also be included.
With an ecosystem they are looking at the broader sense of the word so it not just about innovative people but also about infrastructure and processes. The end goal is to create a flow of information, resources, knowledge and talent within the ecosystem which should lead to sustained co-creation and breakthrough innovations in the longer run.
A total budget of 500 million EUR is foreseen for this part of the third pillar.
Ria.debreucker@vlaio.be
+32 2 553 13 77
Find the contact info on the site of WEWIS
The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.
The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
